Abinaya Kaliappan

Dr. Abinaya Kaliappan

Indian Veterinary Research Institute, Bareilly, India
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
BSBal Krishan Sharma
Bal Krishan Sharma
SRSARAVANAN RAMAKRISHNAN
SARAVANAN RAMAKRISHNAN
AKAbinaya Kaliappan
Abinaya Kaliappan
MSMithilesh Singh
Mithilesh Singh
AKAjay Kumar
Ajay Kumar
MCMadhan Mohan Chellappa
Madhan Mohan Chellappa
Various toll-like receptor (TLR) agonists have shown potential as adjuvants with different vaccines in both human and livestock species, including chickens. Our previous studies on combination of lipopolysaccharide (LPS; TLR4 agonist) and resiquimod (R-848; TLR7 agonist) showed the synergistic up-regulation of pro-inflammatory Th1 and Th2 cytokines in chicken peripheral blood mononuclear cells (PMBCs). Hence, the present study aimed to explore the combined adjuvant effect of LPS and R-848 with inactivated Newcastle disease virus (NDV) vaccine in chickens. Two weeks-old SPF chickens were immunized with inactivated NDV vaccine along with a combination of LPS and R-848 as an adjuvant with suitable control groups. A booster dose was given two weeks later. Antibody responses were assessed by enzyme linked immunosorbent assay (ELISA) and hemagglutination inhibition (HI) test, while cell-mediated immune responses were analyzed by a lymphocyte transformation test (LTT) and flow cytometry following vaccination. Two weeks post-booster, the birds were challenged with a velogenic strain of NDV, and protection against clinical signs, mortality and virus shedding was analyzed. The results indicated that inactivated NDV vaccine with R-848 induced significantly higher humoral and cellular immune responses with 100% protection against mortality and viral shedding following a virulent NDV challenge. However, the combination of LPS and R-848 along with inactivated NDV vaccine produced poor humoral and cellular immune responses and could not afford protection against challenge infection and virus shedding when compared to the vaccine-alone group, indicating the deleterious effects of the combination on antigen-specific immune responses. In conclusion, the combination of LPS and R-848 showed the inhibitory effects on antigen-specific humoral, cellular and protective immune responses when used as an adjuvant with inactivated NDV vaccines in chickens. This inhibitory effect might have occurred due to systemic cytokine storm. A nanoparticle-based delivery of the combination of LPS and R-848 for slow and sustained release could be tried as an alternative method to explore the synergistic effect of the combination as an adjuvant in chickens.

11 November 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
SCShweta Choudhary
Shweta Choudhary
SNSanketkumar Nehul
Sanketkumar Nehul
SNSanthosh Kambaiah Nagaraj
Santhosh Kambaiah Nagaraj
RNRohan Narayan
Rohan Narayan
SVShalja Verma
Shalja Verma
KKK Amith Kumar
K Amith Kumar
Emerging variants of SARS-CoV-2 still threaten the effectiveness of currently deployed vaccines, and antivirals can prove to be an effective therapeutic option for attenuating it. The papain-like protease (PLpro) is an attractive target due to its sequence conservation and critical role in the replication and pathogenesis of SARS-CoV-2. PLpro also plays very important role in modulation of host immune responses by deubiquitinating (DUBs) or deISGylating host proteins. Thus, targeting PLpro serves as a two-pronged approach to abate SARS-CoV-2. Due to its structural and functional similarities with the host DUB enzymes, an in-house library of DUB inhibitors was constituted in this study. Five promising compounds exhibiting high binding affinities with the substrate binding site of PLpro were identified from a library of 81 compounds with in silico screening, docking, and simulation studies. Interestingly, lithocholic acid, linagliptin, teneligliptin, and flupenthixol significantly inhibited the proteolytic activity of PLpro. Each of these compounds abrogated in vitro replication of SARS-CoV-2 with EC50 values in the range of 5-21 μM. In addition, crystal structure of SARS-CoV-2 PLpro and its complex with inhibitors have been determined that revealed their inhibitory mechanism. The findings of this study provide the proof-of-principle that the DUB inhibitors hold high potential as a new class of therapeutics against SARS-CoV-2. Additionally, this is the first study that has opened a new avenue towards not only targeting PLpro active site but also simultaneously directing towards restoration of antiviral immune response of the host for deterring SARS-CoV-2. Graphical abstract

12 March 2024 in Microbiology Resource Announcements
Verified
Journal Article
Open access
SYSarita Yadav
Sarita Yadav
ABAshok Boora
Ashok Boora
PTPrasad Thomas
Prasad Thomas
AKAbinaya Kaliappan
Abinaya Kaliappan
NVNisha Verma
Nisha Verma
PLPuran Chand Lailer
Puran Chand Lailer
We report here the genome sequence of a bubaline herpesvirus 1 isolated from Indian water buffalo. The bubaline herpesvirus 1 strain S102_1 was isolated in 2021 from a Murrah buffalo heifer with clinical presentation of pustular vulvovaginitis.

1 July 2022 in Acta Scientific Veterinary Sciences
Verified
Journal Article
Closed access
MAMarcia Ashmi
Marcia Ashmi
SASanjana
Sanjana
AKAbinaya Kaliappan
Abinaya Kaliappan
PNPatel Nikunjkumar
Patel Nikunjkumar

11 October 2025 in Vaccine
Verified
Journal Article
Closed access
AKAbinaya Kaliappan
Abinaya Kaliappan
SRSARAVANAN RAMAKRISHNAN
SARAVANAN RAMAKRISHNAN
KPKhushboo Panwar
Khushboo Panwar
DNDumala Naveen
Dumala Naveen
PTPrasad Thomas
Prasad Thomas
MCMadhan Mohan Chellappa
Madhan Mohan Chellappa

3 February 2025 in Biochemistry and Biophysics Reports
Verified
Journal Article
Open access
DKDeepthi Kappala
Deepthi Kappala
SRSARAVANAN RAMAKRISHNAN
SARAVANAN RAMAKRISHNAN
PPPatel Nikunjkumar Prakashbhai
Patel Nikunjkumar Prakashbhai
AKAbinaya Kaliappan
Abinaya Kaliappan
PTPrasad Thomas
Prasad Thomas
MCMadhan Mohan Chellappa
Madhan Mohan Chellappa
Resiquimod (R-848), a synthetic TLR7 agonist, modulates immune responses, primarily inducing Th1-biased immunity in mammals. In contrast, our previous studies revealed that R-848 stimulates both Th1 and Th2 responses in chickens. The current research investigates the molecular mechanisms underlying these immune responses in chickens. Pooled splenocytes harvested from chickens (n = 2/group) at 24 h post R-848 treatment were subjected to RNA sequencing and significant differentially expressed genes (DEGs) were identified compared to controls. Eight key genes associated with signal transduction (MAPK14, MAP3K8, PIK3CD, STAT1, STAT3, MAPK11, LRRK2, and GATA3) were validated via real-time PCR in chicken peripheral blood mononuclear cells (PBMCs) from six biological replicates. Pharmacological inhibitors or chloroquine were employed to elucidate the signalling pathways. SB202190, IC-87114, and fludarabine phosphate suppressed the R-848-induced expression of MAPK14, PIK3CD, and STAT1, respectively, while chloroquine decreased STAT3 expression. Intriguingly, chloroquine treatment enhanced the R-848-mediated expression of MAPK11, LRRK2, and GATA3. These results align with transcriptomic findings and highlight the upregulation of STAT1 and STAT3 as potential contributors to the induction of Th1 and Th2 immune responses by R-848 in chickens. These insights provide a foundation for optimizing R-848 as an immunomodulatory agent in avian species.